Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
K Modjarrad, CC Roberts, KT Mills… - The Lancet Infectious …, 2019 - thelancet.com
Summary Background Middle East respiratory syndrome (MERS) coronavirus causes a
highly fatal lower-respiratory tract infection. There are as yet no licensed MERS vaccines or …
highly fatal lower-respiratory tract infection. There are as yet no licensed MERS vaccines or …
[HTML][HTML] Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non …
PM Folegatti, M Bittaye, A Flaxman… - The Lancet Infectious …, 2020 - thelancet.com
Summary Background Cases of Middle East respiratory syndrome coronavirus (MERS-CoV)
infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi …
infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi …
A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates
K Muthumani, D Falzarano, EL Reuschel… - Science translational …, 2015 - science.org
First identified in 2012, Middle East respiratory syndrome (MERS) is caused by an emerging
human coronavirus, which is distinct from the severe acute respiratory syndrome …
human coronavirus, which is distinct from the severe acute respiratory syndrome …
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
T Koch, C Dahlke, A Fathi, A Kupke… - The Lancet Infectious …, 2020 - thelancet.com
Summary Background The Middle East respiratory syndrome coronavirus (MERS-CoV)
causes a respiratory disease with a case fatality rate of up to 35%. Given its potential to …
causes a respiratory disease with a case fatality rate of up to 35%. Given its potential to …
[HTML][HTML] Middle East respiratory syndrome vaccine candidates: cautious optimism
C Schindewolf, VD Menachery - Viruses, 2019 - mdpi.com
Efforts towards developing a vaccine for Middle East respiratory syndrome coronavirus
(MERS-CoV) have yielded promising results. Utilizing a variety of platforms, several vaccine …
(MERS-CoV) have yielded promising results. Utilizing a variety of platforms, several vaccine …
Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)–specific human monoclonal antibody protects rabbits from MERS-CoV infection
KV Houser, L Gretebeck, T Ying, Y Wang… - The Journal of …, 2016 - academic.oup.com
With> 1600 documented human infections with Middle East respiratory syndrome
coronavirus (MERS-CoV) and a case fatality rate of approximately 36%, medical …
coronavirus (MERS-CoV) and a case fatality rate of approximately 36%, medical …
Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind …
JH Beigel, J Voell, P Kumar, K Raviprakash… - The Lancet infectious …, 2018 - thelancet.com
Summary Background Middle East respiratory syndrome (MERS) is a severe respiratory
illness with an overall mortality of 35%. There is no licensed or proven treatment. Passive …
illness with an overall mortality of 35%. There is no licensed or proven treatment. Passive …
Antibodies and vaccines against Middle East respiratory syndrome coronavirus
J Xu, W Jia, P Wang, S Zhang, X Shi… - Emerging microbes & …, 2019 - Taylor & Francis
ABSTRACT The Middle East respiratory syndrome coronavirus (MERS-CoV) has spread
through 27 countries and infected more than 2,200 people since its first outbreak in Saudi …
through 27 countries and infected more than 2,200 people since its first outbreak in Saudi …
DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice
H Chi, X Zheng, X Wang, C Wang, H Wang, W Gai… - Vaccine, 2017 - Elsevier
Abstract The Middle East respiratory syndrome coronavirus (MERS-CoV), is an emerging
pathogen that continues to cause outbreaks in the Arabian peninsula and in travelers from …
pathogen that continues to cause outbreaks in the Arabian peninsula and in travelers from …
Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies
T Ying, L Du, TW Ju, P Prabakaran, CCY Lau… - Journal of …, 2014 - Am Soc Microbiol
ABSTRACT The recently discovered Middle East respiratory syndrome coronavirus (MERS-
CoV) continues to infect humans, with high mortality. Specific, highly effective therapeutics …
CoV) continues to infect humans, with high mortality. Specific, highly effective therapeutics …
相关搜索
- dose escalation safety and immunogenicity
- open label safety and immunogenicity
- dose escalation open label
- middle east safety and immunogenicity
- middle east open label
- middle east antibodies and vaccines
- vaccinia virus safety and immunogenicity
- vaccinia virus open label
- dose escalation coronavirus antibody
- safety and tolerability coronavirus antibody
- dose escalation tolerability of a novel
- dose escalation transchromosomic cattle
- middle east protective immunity
- middle east nonhuman primates
- dose escalation safety and tolerability
- middle east vaccinia virus